Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

被引：75

作者：

Di Castelnuovo, Augusto ^{[1
]}

Costanzo, Simona ^{[2
]}

Antinori, Andrea ^{[3
]}

Berselli, Nausicaa ^{[4
]}

Blandi, Lorenzo ^{[3
]}

Bruno, Raffaele ^{[6
,7
]}

Cauda, Roberto ^{[8
,9
]}

Guaraldi, Giovanni ^{[10
]}

Menicanti, Lorenzo ^{[5
]}

My, Ilaria ^{[11
]}

Parrut, Giustino ^{[9
]}

Patti, Giuseppe ^{[13
]}

Perlini, Stefano ^{[14
,15
]}

Santilli, Francesca ^{[16
,17
]}

Signorelli, Carlo ^{[18
]}

Spinoni, Enrico ^{[13
]}

Stefanini, Giulio G. ^{[11
]}

Vergori, Alessandra ^{[19
]}

Ageno, Walter ^{[20
]}

Agodi, Antonella ^{[21
,22
]}

Aiello, Luca ^{[23
]}

Agostoni, Piergiuseppe ^{[24
,25
]}

Al Moghazi, Samir ^{[26
]}

Astutot, Marinella ^{[21
,22
]}

Aucella, Filippo ^{[27
]}

Barbieri, Greta ^{[28
,29
]}

Bartoloni, Alessandro ^{[30
]}

Bonaccio, Marialaura ^{[2
]}

Bonfanti, Paolo ^{[31
,32
]}

Cacciatore, Francesco ^{[33
]}

Caiano, Lucia ^{[20
]}

Cannata, Francesco ^{[11
]}

Carrozzi, Laura ^{[29
,34
]}

Cascio, Antonio ^{[35
]}

Ciccullo, Arturo ^{[8
]}

Cingolani, Antonella ^{[8
,9
]}

Cipollone, Francesco ^{[16
,17
]}

Colomba, Claudia ^{[35
]}

Crosta, Francesca ^{[12
]}

Dal Praag, Chiara ^{[36
]}

Danzi, Gian Battista ^{[37
]}

D'Ardes, Damiano ^{[16
,17
]}

Donati, Katleen de Gaetano ^{[8
]}

Del Giacomo, Paola ^{[8
]}

Di Gennaro, Francesco ^{[38
]}

Di Tano, Giuseppe ^{[37
]}

D'OFFizi, Giampiero ^{[39
]}

Filippini, Tommaso ^{[4
]}

Fusco, Francesco Maria ^{[40
]}

Gentile, Ivan ^{[41
]}

机构：

[1] Mediterranea Cardioctr, Naples, Italy

[2] IRCCS Neuromed, Dept Epidemiol & Prevent, Pozzilli, IS, Italy

[3] IRCCS, Natl Inst Infect Dis Spallanzani, UOC Immunodeficienze Virali, Rome, Italy

[4] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Sect Publ Hlth, Modena, Italy

[5] IRCCS Policlin San Donato, San Donato Milanese, Italy

[6] Fdn IRCCS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy

[7] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, Pavia, Italy

[8] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[9] Univ Cattolica Sacro Cuore, Dipartimento Sicurezza & Bioet, Sede Roma, Rome, Italy

[10] Univ Modena & Reggio Emilia, Dept Surg, Infect Dis Unit, Modena, Italy

[11] Humanitas Clin & Res Hosp IRCCS, Rozzano Milano, Italy

[12] Azienda Sanitaria Locale AUSL Pescara, Dept Infect Dis, Pescara, Italy

[13] Univ Piemonte Orientale, Maggiore della Carita Hosp, Novara, Italy

[14] IRCCS Policlin San Matteo Fdn, Emergency Dept, Pavia, Italy

[15] Univ Pavia, Dept Internal Med, Pavia, Italy

[16] SS Annunziata Hosp, Dept Med & Aging, Clin Med, Chieti, Italy

[17] Univ G dAnnunzio, Chieti, Italy

[18] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy

[19] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, HIV AIDS Dept, Rome, Italy

[20] Univ Insubria, Dept Med & Surg, Varese, Italy

[21] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy

[22] AOU Policlin Vittorio Emanuele, Catania, Italy

[23] Osped Morgagni Pierantoni, UOC Anestesia & Rianimaz, Dipartimento Chirurg Gen, Forli, Italy

[24] Ctr Cardiol Monzino IRCCS, Milan, Italy

[25] Univ Milan, Dept Clin Sci & Community Hlth, Cardiovasc Sect, Milan, Italy

[26] IRCCS, Infez Sistem Immunodepresso, Natl Inst Infect Dis L Spallanzani, Rome, Italy

[27] Fdn IRCCS Casa Sollievo della Sofferenza, Foggia, Italy

[28] Azienda Osped Univ Pisana, Dept Clin & Expt Med, Pisa, Italy

[29] Univ Pisa, Pisa, Italy

[30] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[31] ASST Monza, Osped San Gerardo, UOC Malattie Infett, Monza, Italy

[32] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy

[33] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy

[34] Azienda Osped Univ Pisana, Cardiovasc & Thorac Dept, Pisa, Italy

[35] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Infect & Trop Dis Unit, Palermo, Italy

[36] Univ Hosp Padova, Dept Med DIMED, Clin Med 3, Padua, Italy

[37] Osped Cremona, Dept Cardiol, Cremona, Italy

[38] IRCCS Neuromed, Med Direct, Pozzilli, IS, Italy

[39] IRCCS, Natl Inst Infect Dis L Spallanzani, UOC Malattie Infett Epatol, Rome, Italy

[40] Azienda Osped Colli, Osped Cotugno, UOC Infez Sistem & Immunodepresso, Naples, Italy

[41] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[42] Univ Padua, Dept Cardiol Thorac & Vasc Sci, Resp Pathophysiol Div, Padua, Italy

[43] PO San Giuseppe Moscati, UOC Pneumol, Taranto, Italy

[44] ASST Milano Nord, Osped Edoardo Bassini, Cinisello Balsamo, Italy

[45] EE Osped Reg F Miulli, COVID 19 Unit, Acquaviva Delle Fonti, BA, Italy

[46] ASL Napoli 1 Ctr, PO S Maria di Loreto Nuovo, UOC Med, Naples, Italy

[47] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Infect & Trop Dis Unit, Catanzaro, Italy

[48] Univ Pisa, Dipartimento Farm, Pisa, Italy

[49] AOU Policlin Vittorio Emanuele, UO C Malattie Infett & Tropicali, PO San Marco, Catania, Italy

[50] IRCCS, Natl Inst Infect Dis L Spallanzani, UOC Malattie Infett Apparat Resp, Rome, Italy

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2020年 / 82卷

关键词：

Hydroxychloroquine; COVID-19; Disease severity; Mortality; Inflammation; VIRAL-INFECTIONS; CHLOROQUINE; REPLICATION;

D O I：

10.1016/j.ejim.2020.08.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective: We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods: In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses. Results: Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR= 0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry. Conclusions: HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.

引用

页码：1 / 10

页数：10

共 41 条

[1] Agenzia Italiana del Farmaco (AIFA), AIFA SOSP AUT ALL UT
[2] Agenzia Italiana del Farmaco (AIFA), IDR NELL TER PAZ AD
[3] Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity
Akpovwa, Hephzibah
[J]. CELL BIOCHEMISTRY AND FUNCTION, 2016, 34 (04) : 191 - 196
[4] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
不详
[J]. PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01): : 9 - 26
[5] [Anonymous], COVID-19 (Coronavirus) Response
[6] Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Arshad, Samia
Kilgore, Paul
Chaudhry, Zohra S.
Jacobsen, Gordon
Wang, Dee Dee
Huitsing, Kylie
Brar, Indira
Alangaden, George J.
Ramesh, Mayur S.
McKinnon, John E.
O'Neill, William
Zervos, Marcus
[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 396 - 403
[7] A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, David R.
Pullen, Matthew F.
Bangdiwala, Ananta S.
Pastick, Katelyn A.
Lofgren, Sarah M.
Okafor, Elizabeth C.
Skipper, Caleb P.
Nascene, Alanna A.
Nicol, Melanie R.
Abassi, Mahsa
Engen, Nicole W.
Cheng, Matthew P.
LaBar, Derek
Lother, Sylvain A.
MacKenzie, Lauren J.
Drobot, Glen
Marten, Nicole
Zarychanski, Ryan
Kelly, Lauren E.
Schwartz, Ilan S.
McDonald, Emily G.
Rajasingham, Radha
Lee, Todd C.
Hullsiek, Kathy H.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) : 517 - 525
[8] A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19
Chowdhury, M. D. Sadakat
Rathod, Jay
Gernsheimer, Joel
[J]. ACADEMIC EMERGENCY MEDICINE, 2020, 27 (06) : 493 - 504
[9] Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
Cipriani, Alberto
Zorzi, Alessandro
Ceccato, Davide
Capone, Federico
Parolin, Matteo
Donato, Filippo
Fioretto, Paola
Pesavento, Raffaele
Previato, Lorenzo
Maffei, Pietro
Saller, Alois
Avogaro, Angelo
Sarais, Cristiano
Gregori, Dario
Iliceto, Sabino
Vettor, Roberto
[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 280 - 284
[10] A systematic review on the ef ficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, Andrea
Ingoglia, Giulia
Ippolito, Mariachiara
Giarratano, Antonino
Einav, Sharon
[J]. JOURNAL OF CRITICAL CARE, 2020, 57 : 279 - 283

← 1 2 3 4 5 →